Company intelligence / Profile preview
Hanhui Pharmaceutical
- Ownership
- Private
- Development stage
- Other
Overview
Hanhui Pharmaceutical has commercialized over 60 products in China across oncology, cardiovascular/cerebrovascular disease, metabolism and other areas. The company was the first in China to localize manufacturing of certain innovator drugs through technology transfer from Pfizer. Several generic and branded drugs have passed national consistency evaluation or been listed as reference drugs. Clinical pipeline includes small molecule programs for neoplasms and metabolic disorders; at least one program has reached IND approval with others approved or in early clinical phases.
- Therapeutic areas
- ImmunologyEndocrinologyHematologyOncologyNeurology
- Modalities
- Small molecule
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Hanhui Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hanhui Pharmaceutical.